MitoQ to Improve Vascular Funciton in Preeclampsia

Part of paid clinical trials in Milwaukee, Wisconsin.

Sponsor
Medical College of Wisconsin
Study ID
NCT07229261
Status
Recruiting
Apply to this trial

Conditions

  • Preeclampsia
  • Pregnancy

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 50 Years
Healthy Volunteers
Not accepted

Interventions

  • Mitoquinol Mesylate — DIETARY_SUPPLEMENT
    Patients randomized to the intervention will receive 10mg of Mitoquinol Mesylate daily from enrollment until delivery.
  • Placebo — OTHER
    Patients randomized to the placebo groups will take 1 placebo capsule daily until delivery.

Study Details

Preeclampsia is a leading cause of maternal and neonatal morbidity and mortality. There is a lack of effective therapeutics for prevention or treatment. Our previous ex vivo work demonstrated that mitochondrial-antioxidants can reverse placental microvascular damage. Therefore, this study will evaluate whether MitoQ (Mitoquinol Mesylate, a mitochondrial-antioxidant) has the potential to restore vasodilation, improve placental function, and therefore promote pregnancy prolongation in patients with preeclampsia. This evaluation of clinical data, patient samples, and vascular function studies in patients with preeclampsia could translate into a viable therapeutic option.

Key Dates

Start date
Mar 18, 2026
Status verified
Apr 2026
Primary completion
Sep 30, 2027
Completion
Sep 30, 2027

Study Design

Enrollment
80 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Preeclampsia with Severe Features taking Mitoquinol Mesylate
    Patients allocated to this arm will be inpatients who have preeclampsia with severe features. They will receive 10mg of Mitoquinol Mesylate daily from enrollment until delivery.
  • Placebo Comparator: Preeclampsia with Severe Features taking placebo
    Patients allocated to this arm will be inpatients who have preeclampsia with severe features. They will receive Placebo daily from enrollment until delivery.
  • Experimental: Preeclampsia without Severe Features taking MitoQ
    Patients allocated to this arm will be out-patients who have preeclampsia without severe features. They will receive 10mg of Mitoquinol Mesylate daily from enrollment until delivery.
  • Placebo Comparator: Preeclampsia without Severe Features taking placebo
    Patients allocated to this arm will be out-patients who have preeclampsia without severe features. They will receive placebo daily from enrollment until delivery.

Primary Outcome Measure

Brachial Artery Flow Mediated Dilation (FMD) [ Time Frame: 1-2 times per week from enrollment until delivery, up to 10 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Froedtert & the Medical College of WisconsinMilwaukeeWisconsin53226
Jennifer McIntosh
[email protected]
4148059019

Find similar trials in Milwaukee, WI

By research site
Froedtert & the Medical College of Wisconsin· Milwaukee, WI

Related Studies